We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01790126
Recruitment Status : Active, not recruiting
First Posted : February 13, 2013
Last Update Posted : August 18, 2017
Sponsor:
Information provided by (Responsible Party):
Aragon Pharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 31, 2019
  Estimated Study Completion Date : January 31, 2020